Week in Review: Sinocare Eyes $4B Deal for J&J Diabetes Device Business

January 22, 2018 |

1 min read

Sinocare of Changsha may bid as much as $4B to acquire J&J’s diabetes medical device subsidiaries

January 20, 2018

Deals and Financings

Sinocare of Changsha may bid as much as $4 billion to acquire Johnson & Johnson’s diabetes medical device subsidiaries;
China’s Ping An Healthcare Management closed a nearly $1 billion pre-IPO round for its healthcare platform and plans a Hong Kong IPO later in the year;
BeiGene, a Beijing novel cancer company, raised $750 million in a secondary offering, giving the company a $5.5 billion valuation;
Innovent Biologics of Suzhou is planning a pre-IPO round and then a $200 million IPO in late 2018 on either a US or Hong Kong exchange;
BeiGene in-licensed Asian rights to a clinical-stage lung cancer therapy from Mirati Therapeutics of San Diego in a $133 million deal;
Ascletis, a Hangzhou company developing a oral interferon-free combination treatment for hepatitis C, is planning a $100 million pre-IPO C round;
Suzhou Zelgen Biosciences completed a $62 million series B financing to support its portfolio of small molecule and biologic drug candidates;
Vaccitech, an Oxford University spinout developing a universal flu vaccine, closed a $27 million Series A round that included China investors;
Adlai Nortye Biopharma of Hangzhou acquired global rights to a novel immuno-oncology oral EP4 antagonist from Japan’s Eisai;
Shenyang’s 3SBio in-licensed China rights to a pruritis (itching) treatment developed by Toray of Japan for dialysis patients;
CR Pharma, China’s second-largest drugmaker, is negotiating with Sweden’s Xbrane Biopharma for China rights to two drug candidates;